<DOC>
	<DOCNO>NCT00039195</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Monoclonal antibody rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Combining chemotherapy monoclonal antibody therapy , total-body irradiation , peripheral stem cell transplant may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : This phase II trial study well give chemotherapy rituximab follow combination chemotherapy without rituximab , total-body irradiation , peripheral stem cell transplant work treat patient lymphoma .</brief_summary>
	<brief_title>Chemotherapy Rituximab With Without Total-Body Irradiation Peripheral Stem Cell Transplant Treating Patients With Lymphoma</brief_title>
	<detailed_description>OUTLINE : Patients stratify accord risk ( low-intermediate v high-intermediate high ) . Patients receive induction chemotherapy comprise cyclophosphamide IV , doxorubicin IV 15 minute , vincristine IV 1-2 minute day 1 ; oral prednisone daily day 1-5 ; filgrastim ( G-CSF ) subcutaneously ( SC ) daily day 7-11 PEG-filgrastim least 24 hour infusion . Patients also receive rituximab IV 2-3 day apart total 2 dos week prior first course chemotherapy day 1 course 2-4 chemotherapy . Treatment repeat every 14 day total 4 course absence disease progression unacceptable toxicity . After completion induction chemotherapy , patient undergo CT scan positron emission tomography ( PET ) scanning . If PET scan positive one nodal sit , repeat biopsy perform . Patients negative PET scan OR negative repeat biopsy ( include evidence lymphoma repeat bone marrow biopsy ) assign receive regimen A consolidation therapy . Patients positive repeat biopsy assign receive regimen B consolidation therapy . - Regimen A : Patients receive consolidation chemotherapy comprise etoposide IV 1 hour day 1-3 , ifosfamide IV continuously 24 hour day 2 , carboplatin IV day 2 , G-CSF SC daily day 5-12 PEG-filgrastim least 24 hour infusion . Treatment repeat every 14 day total 3 course absence disease progression unacceptable toxicity . - Regimen B : Patients receive consolidation chemotherapy regimen A 3 course . Patients also receive rituximab IV day -3 -1 course 3 chemotherapy . Patients undergo leukapheresis completion course 3 ( G-CSF continue day 5 end leukapheresis ) . After completion leukapheresis , patient begin regimen high-dose chemoradiotherapy comprise either total body irradiation twice daily day -10 -7 ifosfamide IV 1 hour etoposide IV continuously day -6 -2 BEAM chemotherapy comprise carmustine , etoposide , cytarabine , melphalan . Autologous peripheral blood stem cell ( APBSC ) reinfused day 0 . Patients also receive G-CSF SC daily begin day 5 continue blood count recover . Beginning day 42 post-APBSC , blood count recover , patient receive rituximab IV weekly 4 week . Rituximab repeat begin day 180 absence disease progression . Patients receive consolidation therapy regimen A followed 4-6 week chemotherapy patient receive consolidation therapy regimen B follow 90-120 day transplantation . All patient follow closely 5 year annually thereafter . PROJECTED ACCRUAL : A total 40-98 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm aggressive diffuse large Bcell lymphoma CD20positive disease Ageadjusted International Prognostic Index II III define presence least 1 follow : Karnofsky performance status 1070 % Lactate dehydrogenase great 200 U/L Stage III IV disease Positron emission tomography avid measurable disease No CNS involvement PATIENT CHARACTERISTICS : Age : 18 64 Performance status : See Disease Characteristics Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1,000/mm^3 Platelet count great 50,000/mm^3 Hepatic : Bilirubin le 2.0 mg/dL unless history Gilbert 's disease pattern consistent Gilbert 's disease Hepatitis B surface antigen hepatitis C antibody negative No chronic , active , persistent hepatitis Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance great 60 mL/min No chronic renal insufficiency Cardiovascular : Ejection fraction least 50 % echocardiogram MUGA scan No myocardial infarction within past 6 month No unstable angina No cardiac arrhythmias except chronic atrial fibrillation Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception HIV negative No medical illness would preclude study No uncontrolled infection No malignancy within past 5 year except curatively treat basal cell squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy malignancy Chemotherapy : No prior chemotherapy malignancy Endocrine therapy : Prior steroid allow receive 1 week therapy Radiotherapy : No prior radiotherapy malignancy Surgery : No prior surgery malignancy Other : No prior therapy malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
</DOC>